Real-World Experience With Janus Kinase Inhibitors in Immune-Mediated Diseases: Clinical Experience of a University Hospital
Our real-world data show that treatment with JAK inhibitors leads to a high rate of remission/low activity that remains unchanged at six to 12 months in RA, SpA, and PsA. The predictors of a poor response to JAK inhibitors in our study population were the level of activity before initiation of treatment and previous failure of bDMARDs. No cardiovascular or thromboembolic events were reported. Of note, we did record one case of severe infection, one case of basal cell carcinoma, and two cases of herpes zoster.
Authors
- David Castro Corredor (ORCID: https://orcid.org/0000-0001-7315-6274)
- L. Jiménez Rodríguez
- L. Á. Calvo Pascual
- Marco Aurelio Ramírez Huaranga (ORCID: https://orcid.org/0000-0002-7243-7565)
- Alberto López Menchero Mora
- Marina González Peñas (ORCID: https://orcid.org/0000-0001-6247-6344)
- David Velasco Sánchez
- Lourdes Martin de la Sierra López
Institutions
- Hospital General Universitario de Ciudad Real (ES)
- Universidad Pontificia Comillas (ES)
Publication Details
- Journal
- Cureus
- Published
- 2024-08-25
- DOI
- https://doi.org/10.7759/cureus.67729
- Citations
- 2
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Fundación Española de Reumatología